Red Light Holland and Kala Bio Announce AI Engagement
Red Light Holland Corp. and Kala Bio, Inc. announced on March 18, 2026, that Red Light has engaged Kala Bio’s Researgency.ai platform, under worldwide license from Younet, to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp., according to GlobeNewswire PE. The engagement will deploy Kala Bio’s AI research agents for clinical planning, protocol optimization, and scenario modeling as Red Light advances PEX010 through its regulated drug development program. Red Light recently announced a definitive arrangement agreement to acquire Filament’s business, including its portfolio of 76 issued patents across 15 patent families.
Strategic Use of AI in Drug Development
The engagement represents a key element of Red Light’s strategy to integrate advanced AI-driven research capabilities as it expands its regulated psychedelic drug development platform. Kala Bio’s Researgency.ai platform uses custom purpose-built AI agents trained by Younet engineers in collaboration with Kala and operates under private cloud LLM infrastructure supplied by Kala. PEX010 is supplied to more than 70 clinical research sites worldwide and is being studied for indications such as alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder at institutions including Johns Hopkins University and Dana-Farber Cancer Institute.
PEX010’s Regulatory and Clinical Status
PEX010 has received authorization from Health Canada and the U.S. Food and Drug Administration for clinical trials and has demonstrated positive Phase 2 clinical data in alcohol use disorder, according to GlobeNewswire PE. This drug candidate is one of the most widely studied botanical psilocybin options in regulated clinical research. As a widely-known context, psilocybin research has gained attention in mental health treatments, though this engagement specifically focuses on enhancing Red Light’s development processes through AI.
